Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus GATIFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus GATIFLOXACIN.
CIPROFLOXACIN HYDROCHLORIDE vs GATIFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
500-750 mg orally every 12 hours; 400 mg intravenously every 8-12 hours.
400 mg orally or intravenously once daily
None Documented
None Documented
Terminal half-life 4 hours (3-5 h) in normal renal function; prolonged to 5-10 h in mild-to-moderate renal impairment and >10 h in severe impairment (CrCl <30 mL/min).
Clinical Note
moderateGatifloxacin + Digoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGatifloxacin + Digitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGatifloxacin + Deslanoside
"Gatifloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGatifloxacin + Acetyldigitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 7-14 hours (mean ~10 hours in healthy adults); prolonged in renal impairment (up to 40 hours with CrCl <30 mL/min)
Renal: 50-70% unchanged drug; biliary/fecal: 15-25% (partly as metabolites).
Primarily renal excretion (70-87% unchanged in urine) via glomerular filtration and tubular secretion; ~10% biliary/fecal
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic